311, H1431H1436
To view or add a comment, sign in Oral semaglutide at a dose of 25mg daily approved by the FDA today for the treatment of obesity Expected to launch January 2026 To view or add a comment, sign in Oral Wegovy when it gets launched will remove needle barriers, dramatically improving access, acceptance, and early obesity treatment across Indias needle-phobic population
The injection can be given in the abdomen, thigh, or upper arm
It features ingredients such as Astragalus, Dangshen, and Huo Xiang
In a Phase I single-blind, placebo-controlled trial, 3 male volunteers received subcutaneous MT-2 injections (0.01-0.03 mg/kg) on alternating days for 2 weeks
The medication comes from licensed 503A compounding pharmacies, requires no insurance, and is eligible for HSA and FSA funds